Chemotherapy News and Research

Latest Chemotherapy News and Research

Pediatric treatment regime for ALL patients improves chances of long-term survival

Acute lymphoblastic leukemia (ALL), usually found in pediatric patients, is far more rare and deadly in adolescent and adult patients. According to the National Marrow Donor Program, child ALL patients have a higher than 80 percent remission rate, while the recovery rate for adults stands at only 40 percent.

18 Jun 2012

Multi-institutional research uncovers new mechanism for treatment of lung cancer

A multi-institutional research study has uncovered a new mechanism that may lead to unique treatments for lung cancer, one of the leading causes of death worldwide.

18 Jun 2012

Zealand Pharma, Protagonist partner to develop novel disulfide-rich peptides

Zealand Pharma A/S, a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, has signed a collaboration agreement with Protagonist Therapeutics, Inc., a privately-owned US incorporated biotechnology company.

18 Jun 2012

CINJ commences enrollment in three-drug combination trial for breast cancer

Researchers at The Cancer Institute of New Jersey (CINJ) are enrolling patients for a clinical trial, which aims to evaluate a new drug for breast cancer that has spread (metastatic) in combination with two chemotherapy agents called doxorubicin and cyclophosphamide.

18 Jun 2012

Is curry good for you?

There have been several news stories over the years reporting that curry may be good for us. Most of them refer to a chemical in curry, known as curcumin.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

18 Jun 2012

Researchers engineer nanoparticles that show great promise for MM

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

16 Jun 2012

Researchers identify three sets of genetic markers linked with CNS PNET

Researchers at The University of Nottingham have identified three sets of genetic markers that could potentially pave the way for new diagnostic tools for a deadly type of brain tumour that mainly targets children.

16 Jun 2012

Chemotherapy improves survival for patients with SCLC and LCNEC

Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with limited stage small-cell lung cancer who were treated with perioperative chemotherapy and surgery had better overall survival outcomes than patients treated with surgery alone.

16 Jun 2012

Osiris receives consent from NZ to market Prochymal for GvHD

Osiris Therapeutics, Inc., announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

15 Jun 2012

AMPK enzyme promotes survival of cancer cells: Research

A molecule thought to limit cell proliferation also helps cancer cells survive during initial tumor formation and when the wayward cells spread to other organs in the body, researchers at the University of Illinois at Chicago College of Medicine have found.

15 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Study shows how cisplatin prevents clumping of hSOD1 linked to ALS

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.

14 Jun 2012

New combination therapy can help improve cure rates for neuroblastoma

An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma - a deadly, hard-to-cure childhood cancer.

13 Jun 2012